Niacin—the B-vitamin often taken as a supplement to reduce triglycerides—appears to increase mortality risk, according to a study published in the New England Journal of Medicine. Researchers investigated the effects of an extended-release niacin on 25,673 participants as part of the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study over four years. Those who took the niacin drug had a 9 percent increased risk for death, compared with the placebo group. Niacin did not reduce the risk of heart attack or stroke.
The HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212.
Lloyd-Jones DM. Niacin and HDL cholesterol—time to face facts. N Engl J Med. 2014;371:271-273.
Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014;371:288-290.
Breaking Medical News is a service of the Physicians Committee for Responsible Medicine, 5100 Wisconsin Ave., Ste. 400, Washington, DC 20016, 202-686-2210. Join the Physicians Committee and receive the quarterly magazine, Good Medicine.